Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova PLC (NASDAQ: LIVN) reported a strong performance for Q2 2021, with worldwide sales increasing 45.2% to $264.5 million. Excluding the divested Heart Valves business, sales rose 51.6% to $249.8 million. Neuromodulation sales surged 102.4%, reflecting a recovery in procedure volumes. However, the company posted a GAAP loss per share of $1.13. LivaNova has updated its 2021 guidance, anticipating net sales growth of 5-10% and adjusted earnings per share of $1.60-$1.90. Alex Shvartsburg has been appointed CFO, effective August 1, bringing 25 years of industry experience.
LivaNova PLC (NASDAQ:LIVN) will host a conference call to discuss its second quarter 2021 results on July 28, 2021, at 1 p.m. London time (8 a.m. EDT). The results will be released prior to the call. A live audiocast will be accessible on the company’s website. Participants are encouraged to log on 10 minutes early for setup. To join by phone, dial 844-558-0159 (U.S./Canada) or 236-714-3182 (international) with conference ID 3308297. Replays will be available for 90 days.
LivaNova PLC (NASDAQ:LIVN) has received FDA approval to launch the OSPREY clinical study for its aura6000® System, aimed at treating moderate to severe obstructive sleep apnea (OSA). This system provides a less restrictive alternative to CPAP machines by using an implantable pulse generator to stimulate the hypoglossal nerve, helping keep airways open during sleep. The randomized controlled trial will take place at about 20 sites across the U.S. and enroll up to 150 patients. OSA affects roughly one billion people globally, creating a significant market opportunity for innovative treatments.
LivaNova PLC (NASDAQ:LIVN) has completed the initial closing of its heart valve (HV) business divestiture to Gyrus Capital for €60 million (approx. $73 million). This strategic move allows LivaNova to concentrate on its core cardiovascular and neuromodulation markets. The HV business, expected to generate $70 million in net revenues, will transition 850 employees to Gyrus's newly formed company, CORCYM. Post-divestiture, LivaNova anticipates full-year adjusted EPS between $1.31 to $1.81, reflecting a dilution of approximately $0.09 due to the sale.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the UBS Global Healthcare Virtual Conference on May 25 at 8 a.m. ET. This presentation is accessible to the public via a live webcast on the LivaNova website. Interested listeners are advised to log in 10 minutes early for setup. The webcast will be available for replay for 30 days following the event. LivaNova, headquartered in London, is a leading medical technology company dedicated to improving patient lives globally with a workforce of approximately 4,000 employees.
LivaNova PLC (NASDAQ: LIVN) reported a 2.1% increase in worldwide sales for Q1 2021, totaling $247.6 million, but a decline of 0.4% on a constant-currency basis. The company experienced a diluted loss per share of $0.61 under GAAP, while adjusted diluted EPS was $0.35, up from $0.33 in Q1 2020. Notably, Neuromodulation sales rose by 15.7%, while Cardiovascular sales fell by 9.4%. For 2021, LivaNova anticipates net sales growth between 8% and 13%, reaffirming its full-year guidance.
LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.
LivaNova PLC (NASDAQ:LIVN) announced the randomization of the 300th patient in its ANTHEM-HFrEF Pivotal Study, aiming to evaluate Autonomic Regulation Therapy (ART) for heart failure treatment. This FDA-approved study will analyze the effectiveness of Vagus Nerve Stimulation (VNS) on symptoms and clinical outcomes in heart failure patients with reduced ejection fraction. The VITARIA System, designed for ART delivery, may become a first-in-class device if approved. Notable clinical outcomes include symptom relief and reduced hospitalizations.
LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will host a conference call on April 28, 2021, at 12 p.m. London time (7 a.m. EDT) to discuss its Q1 2021 results. The results will be released prior to the call. Interested listeners can access a live audiocast via the Investors section of LivaNova's website. The dial-in numbers include 844-558-0159 for U.S. and Canada and 236-714-3182 for other regions, with a conference ID of 6493742. A replay will be available for 90 days following the call.
LivaNova PLC (NASDAQ: LIVN) reported a Q4 2020 revenue of $269.6 million, a 6.3% decline compared to Q4 2019, impacted by COVID-19. The diluted loss per share was $5.74, while adjusted EPS was $0.71. Cardiovascular sales fell by 10.1%, with Heart Valves down 27.2%, but Advanced Circulatory Support saw a 50.3% increase. For FY 2020, total sales decreased by 13.8% to $934.2 million. Looking ahead, LivaNova forecasts 2021 sales growth of 8-13% and adjusted EPS between $1.40 and $1.90, despite ongoing COVID-related uncertainties.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
